Immunic Appoints Jon Congleton to Board of Directors
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy IMUX?
Immunic (IMUX) announced the appointment of Jon Congleton to its board of directors, effective March 27. Congleton currently serves as CEO and member of the board of directors of Mineralys Therapeutics (MLYS)
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IMUX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IMUX
Wall Street analysts forecast IMUX stock price to rise
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.030
Low
3.00
Averages
4.25
High
8.00
Current: 1.030
Low
3.00
Averages
4.25
High
8.00
About IMUX
Immunic, Inc. is a biotechnology company developing a clinical pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The Company is engaged in pursuing clinical development of programs, which include the vidofludimus calcium (IMU-838) program, which is in Phase III clinical development for patients with relapsing multiple sclerosis (RMS), and which has shown therapeutic activity in Phase II clinical trials in patients suffering from relapsing-remitting MS, progressive MS and moderate-to-severe ulcerative colitis; the IMU-856 program, which is targeted to regenerate bowel epithelium and restore intestinal barrier function, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, Graft-versus-Host-Disease and weight management, and the IMU-381 program, which is a molecule being developed to specifically address the needs of gastrointestinal diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Immunic Regains Nasdaq Compliance with Minimum Bid Price
- Compliance Notification: Immunic received a notice from Nasdaq on March 27, 2026, confirming its compliance with the minimum bid price requirement, as its common stock closed at $1.00 or above for 20 consecutive business days, indicating stability in its capital market presence.
- Clinical Trial Progress: The company's lead program, vidofludimus calcium (IMU-838), is currently in phase 3 trials for relapsing multiple sclerosis, with top-line data expected by the end of 2026, which could significantly impact its future market performance.
- Innovative Drug Mechanism: As a first-in-class Nurr1 activator, the drug combines neuroprotective effects with anti-inflammatory and antiviral properties by selectively inhibiting dihydroorotate dehydrogenase (DHODH), showcasing its potential in treating various neurological diseases.
- Diverse R&D Pipeline: In addition to IMU-838, Immunic is developing earlier-stage programs like IMU-856 and IMU-381, aimed at building a broader therapeutics platform to address neurodegenerative, chronic inflammatory, and autoimmune diseases, thereby enhancing the company's competitive edge in the market.
See More
Immunic Regains Nasdaq Compliance with Minimum Bid Price
- Compliance Notification: Immunic received written notice from Nasdaq confirming that its common stock's closing bid price was at or above $1.00 per share for at least 20 consecutive business days, thereby satisfying Nasdaq's minimum bid price requirement and marking a significant compliance milestone for the company.
- Stock Price Surge: Following the compliance notification, Immunic's stock price rose 5.4% in premarket trading to $1.17 per share, indicating a positive market reaction to the restoration of compliance status, which may enhance investor confidence.
- Funding Context: Immunic recently completed a $400 million private placement, providing essential funding for future R&D and operations, further solidifying its market position and laying the groundwork for subsequent growth.
- Analyst Rating: Guggenheim recently assigned a
See More
Immunic Regains Nasdaq Compliance, Shares Rise
- Compliance Regained: Immunic, Inc. announced on March 26 that it has regained compliance with Nasdaq listing rules after its stock closed at or above $1 for 20 consecutive trading days, alleviating concerns about potential delisting and boosting investor confidence.
- Stock Price Surge: Following the compliance announcement, Immunic's shares rose approximately 6% in pre-market trading on Wednesday, indicating market optimism regarding the company's future prospects and potentially attracting more investor interest.
- Board Appointment: The company appointed Jon Congleton, CEO of Mineralys Therapeutics, to its board on Tuesday, aiming to bring in new leadership perspectives to drive strategic development and enhance governance.
- Market Dynamics: With compliance issues resolved, Immunic is positioned for stable growth on the Nasdaq Capital Market, further expanding its market share and enhancing brand influence.
See More
Immunic Regains Nasdaq Compliance with Minimum Bid Price
- Compliance Notification: Immunic received written notice from Nasdaq on March 27, 2026, confirming its compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2), indicating stability in its capital market presence.
- Stock Price Performance: The notice states that Immunic's common stock closed at $1.00 or greater for at least 20 consecutive business days prior to March 26, 2026, successfully meeting Nasdaq's requirements and closing the related matter.
- Clinical Trial Progress: The company's lead development program, vidofludimus calcium (IMU-838), is currently in phase 3 clinical trials for relapsing multiple sclerosis, with top-line data expected by the end of 2026, which could positively impact future revenues.
- Pipeline Expansion: In addition to IMU-838, Immunic is developing earlier-stage programs IMU-856 and IMU-381, aimed at building a broader therapeutic platform to address neurodegenerative, chronic inflammatory, and autoimmune-related diseases, enhancing its competitive position in the market.
See More
Immunic Appoints Biopharmaceutical Expert Jon Congleton to Board
- New Board Member: Immunic appointed Jon Congleton to its Board of Directors effective March 27, 2026, bringing nearly 40 years of biopharmaceutical experience, particularly in CNS leadership, which will provide strategic advantages for the company.
- Drug Development Experience: Congleton played a key role in the U.S. launch of Teva's Copaxone®, which became the most prescribed treatment for multiple sclerosis, and this experience will aid Immunic in advancing its critical clinical milestones.
- Clinical Trial Progress: Immunic's lead development program, vidofludimus calcium, is currently in phase 3 clinical trials, with top-line data expected by the end of 2026, and Congleton's addition is anticipated to accelerate this process.
- Market Potential: As the first Nurr1 activator, vidofludimus calcium offers unique neuroprotective, anti-inflammatory, and antiviral effects, expected to provide superior treatment options for multiple sclerosis patients, enhancing the company's competitive position in the market.
See More
Immunic Appoints New Board Member with Extensive Biopharmaceutical Experience
- New Board Member: Immunic, Inc. appointed Jon Congleton to its Board of Directors effective March 27, 2026, bringing nearly 40 years of biopharmaceutical experience, including key involvement in the U.S. launch of Copaxone®, which is expected to enhance the company's leadership and industry knowledge.
- Clinical Trial Advancement: Congleton's appointment comes at a critical juncture for Immunic as it advances its lead product, vidofludimus calcium, currently in phase 3 clinical trials, with top-line data expected by the end of 2026, potentially impacting multiple sclerosis patients significantly.
- Market Potential: Vidofludimus calcium, as a first-in-class Nurr1 activator, combines neuroprotective, anti-inflammatory, and antiviral effects, showing promise over existing therapies, and Congleton's expertise is anticipated to accelerate its commercialization process.
- Strategic Development Focus: Immunic aims to leverage Congleton's experience to transition into a fully integrated commercial-stage company, enhancing its competitiveness in the neurological disease treatment market to meet the growing needs of patients.
See More
Immunic Regains Nasdaq Compliance with Minimum Bid Price
- Compliance Notification: Immunic received a notice from Nasdaq on March 27, 2026, confirming its compliance with the minimum bid price requirement, as its common stock closed at $1.00 or above for 20 consecutive business days, indicating stability in its capital market presence.
- Clinical Trial Progress: The company's lead program, vidofludimus calcium (IMU-838), is currently in phase 3 trials for relapsing multiple sclerosis, with top-line data expected by the end of 2026, which could significantly impact its future market performance.
- Innovative Drug Mechanism: As a first-in-class Nurr1 activator, the drug combines neuroprotective effects with anti-inflammatory and antiviral properties by selectively inhibiting dihydroorotate dehydrogenase (DHODH), showcasing its potential in treating various neurological diseases.
- Diverse R&D Pipeline: In addition to IMU-838, Immunic is developing earlier-stage programs like IMU-856 and IMU-381, aimed at building a broader therapeutics platform to address neurodegenerative, chronic inflammatory, and autoimmune diseases, thereby enhancing the company's competitive edge in the market.
See More
Immunic Regains Nasdaq Compliance with Minimum Bid Price
- Compliance Notification: Immunic received written notice from Nasdaq confirming that its common stock's closing bid price was at or above $1.00 per share for at least 20 consecutive business days, thereby satisfying Nasdaq's minimum bid price requirement and marking a significant compliance milestone for the company.
- Stock Price Surge: Following the compliance notification, Immunic's stock price rose 5.4% in premarket trading to $1.17 per share, indicating a positive market reaction to the restoration of compliance status, which may enhance investor confidence.
- Funding Context: Immunic recently completed a $400 million private placement, providing essential funding for future R&D and operations, further solidifying its market position and laying the groundwork for subsequent growth.
- Analyst Rating: Guggenheim recently assigned a
See More
Immunic Regains Nasdaq Compliance, Shares Rise
- Compliance Regained: Immunic, Inc. announced on March 26 that it has regained compliance with Nasdaq listing rules after its stock closed at or above $1 for 20 consecutive trading days, alleviating concerns about potential delisting and boosting investor confidence.
- Stock Price Surge: Following the compliance announcement, Immunic's shares rose approximately 6% in pre-market trading on Wednesday, indicating market optimism regarding the company's future prospects and potentially attracting more investor interest.
- Board Appointment: The company appointed Jon Congleton, CEO of Mineralys Therapeutics, to its board on Tuesday, aiming to bring in new leadership perspectives to drive strategic development and enhance governance.
- Market Dynamics: With compliance issues resolved, Immunic is positioned for stable growth on the Nasdaq Capital Market, further expanding its market share and enhancing brand influence.
See More
Immunic Regains Nasdaq Compliance with Minimum Bid Price
- Compliance Notification: Immunic received written notice from Nasdaq on March 27, 2026, confirming its compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2), indicating stability in its capital market presence.
- Stock Price Performance: The notice states that Immunic's common stock closed at $1.00 or greater for at least 20 consecutive business days prior to March 26, 2026, successfully meeting Nasdaq's requirements and closing the related matter.
- Clinical Trial Progress: The company's lead development program, vidofludimus calcium (IMU-838), is currently in phase 3 clinical trials for relapsing multiple sclerosis, with top-line data expected by the end of 2026, which could positively impact future revenues.
- Pipeline Expansion: In addition to IMU-838, Immunic is developing earlier-stage programs IMU-856 and IMU-381, aimed at building a broader therapeutic platform to address neurodegenerative, chronic inflammatory, and autoimmune-related diseases, enhancing its competitive position in the market.
See More
Immunic Appoints Biopharmaceutical Expert Jon Congleton to Board
- New Board Member: Immunic appointed Jon Congleton to its Board of Directors effective March 27, 2026, bringing nearly 40 years of biopharmaceutical experience, particularly in CNS leadership, which will provide strategic advantages for the company.
- Drug Development Experience: Congleton played a key role in the U.S. launch of Teva's Copaxone®, which became the most prescribed treatment for multiple sclerosis, and this experience will aid Immunic in advancing its critical clinical milestones.
- Clinical Trial Progress: Immunic's lead development program, vidofludimus calcium, is currently in phase 3 clinical trials, with top-line data expected by the end of 2026, and Congleton's addition is anticipated to accelerate this process.
- Market Potential: As the first Nurr1 activator, vidofludimus calcium offers unique neuroprotective, anti-inflammatory, and antiviral effects, expected to provide superior treatment options for multiple sclerosis patients, enhancing the company's competitive position in the market.
See More
Immunic Appoints New Board Member with Extensive Biopharmaceutical Experience
- New Board Member: Immunic, Inc. appointed Jon Congleton to its Board of Directors effective March 27, 2026, bringing nearly 40 years of biopharmaceutical experience, including key involvement in the U.S. launch of Copaxone®, which is expected to enhance the company's leadership and industry knowledge.
- Clinical Trial Advancement: Congleton's appointment comes at a critical juncture for Immunic as it advances its lead product, vidofludimus calcium, currently in phase 3 clinical trials, with top-line data expected by the end of 2026, potentially impacting multiple sclerosis patients significantly.
- Market Potential: Vidofludimus calcium, as a first-in-class Nurr1 activator, combines neuroprotective, anti-inflammatory, and antiviral effects, showing promise over existing therapies, and Congleton's expertise is anticipated to accelerate its commercialization process.
- Strategic Development Focus: Immunic aims to leverage Congleton's experience to transition into a fully integrated commercial-stage company, enhancing its competitiveness in the neurological disease treatment market to meet the growing needs of patients.
See More
